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Abstract
Background: The cerebral microvascular occlusion elicits microvascular injury which mimics the different degrees of
stroke severity observed in patients, but the mechanisms underlying these embolic injuries are far from understood.
The Fas ligand (FasL)-Fas system has been implicated in a number of pathogenic states. Here, we examined the
contribution of microglia-derived FasL to brain inflammatory injury, with a focus on the potential to suppress the FasL
increase by inhibition of the P2X7-FasL signaling with pharmacological or genetic approaches during ischemia.
Methods: The cerebral microvascular occlusion was induced by microsphere injection in experimental animals.
Morphological changes in microglial cells were studied immunohistochemically. The biochemical analyses were used
to examine the intracellular changes of P2X7/FasL signaling. The BV-2 cells and primary microglia from mice genetically
deficient in P2X7 were used to further establish a linkage between microglia activation and FasL overproduction.
Results: The FasL expression was continuously elevated and was spatiotemporally related to microglia activation
following microsphere embolism. Notably, P2X7 expression concomitantly increased in microglia and presented a
distribution pattern that was similar to that of FasL in ED1-positive cells at pathological process of microsphere
embolism. Interestingly, FasL generation in cultured microglia cells subjected to oxygen-glucose deprivation-treated
neuron-conditioned medium was prevented by the silencing of P2X7. Furthermore, FasL induced the migration of BV-2
microglia, whereas the neutralization of FasL with a blocking antibody was highly effective in inhibiting ischemia-
induced microglial mobility. Similar results were observed in primary microglia from wild-type mice or mice genetically
deficient in P2X7. Finally, the degrees of FasL overproduction and neuronal death were consistently reduced in P2X7
−/−
mice compared with wild-type littermates following microsphere embolism insult.
Conclusion: FasL functions as a key component of an immunoreactive response loop by recruiting microglia to the
lesion sites through a P2X7-dependent mechanism. The specific modulation of P2X7/FasL signaling and aberrant
microglial activation could provide therapeutic benefits in acute and subacute phase of cerebral microembolic injury.
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Introduction
Epidemiological and clinical evidence has indicated that
cerebral microvascular occlusion is a common
phenomenon throughout life, which might require better
understanding as a mechanism of ischemic insult and
subsequent neuronal damage [1-3]. Unlike the lethal
larger artery occlusion, microsphere embolism elicits
microvascular injury which mimics the different degrees
of stroke severity observed in patients [2,4-6], but the
mechanisms underlying these embolic injuries are far
from understood. Cerebral ischemia is followed by de-
struction of microvasculature and subsequent inflamma-
tory events during acute and subacute stages of ischemia
[3,7,8]. It is noteworthy that there is a growing body of
evidence that uncontrolled inflammatory response in the
brain can contribute to exacerbate the neuronal loss in
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cerebral ischemia [3,7,8]. The spatiotemporal changes in
microglial dynamics are dramatically affected by capil-
lary blood flow around the microglial somata in intact
ischemic mouse neocortex [9]. However, no link be-
tween brain inflammatory response and cerebral micro-
vascular occlusion has been studied thus far.
The Fas ligand (FasL)-Fas system may play a role in
both physiological and pathological situations in the
brain [10,11], whether and how FasL-Fas system influ-
ences the pathogenesis of microembolic injuries remains
unknown. In pathological conditions, dysregulated FasL-
Fas system leads to activation of Fas-associated death
domain (FADD), caspase 8, and subsequently neuronal
death [12,13]. By contrast, depending on the cell type
and its state, FasL-Fas system has also been shown to be
instructive signal for ongoing and injury-induced brain
regeneration [10]. Despite the autocrine action of FasL
that has been shown in vascular smooth muscle cells
[14], epithelial cells [15], lymphocytes [16], and intestinal
cells [17], little is known about its effects on microglia
or its possible role in brain microembolic injury. Due to
the dual and insufficient knowledge about FasL-Fas sys-
tem in the brain, discrete targets amenable to ischemic
processes need to be identified and functionally
validated.
Microglial cell activation is a rapidly occurring cellular
response to cerebral ischemia, which is a strictly con-
trolled event [18-22]. Activated microglia may exert a
cytotoxic effector function by stimulating morphological
changes and the production of a wide array of inflamma-
tory cytokines, which may cause bystander damage follow-
ing ischemia [18,21]. The mechanisms by which microglia
are activated during the acute and subacute phase of brain
ischemia, or by which microglia continue to synthase or
secrete FasL remain unknown. The exposure of microglia
to H2O2 or paraquat rapidly triggers FasL mRNA tran-
scription and protein expression and also activates NF-
kappa B [23,24]. However, activated microglia under cer-
tain circumstances may act on different steps in the for-
mation, maturation, and functional integration of the new
neurons of both intact and pathological brain [25]. The
opposing neurotoxic and neuroprotective properties of
microglia during ischemic injury provide a rich and cur-
rently unexplored set of research problems.
The present study investigated the pathophysiological
relevance of cerebral microembolic injury-induced micro-
glial activation, FasL intracellular signaling, and the neur-
onal death cascade. We examined the influence of
ischemic injury on microglia cells as well as the functional
outcome of aberrant FasL signaling in vitro and in vivo.
Herein, we report that the activation of P2X7 in microglia
results in a gradual accumulation and release of FasL
along with the subsequent activation of downstream cas-
cades in ischemic context.
Materials and methods
Reagents
All chemicals were purchased from Sigma-Aldrich Chem-
ical Co. (St Louis, MO, USA) unless otherwise noted.
Mouse strains
Homozygous P2X7
−/− mice (B6.129P2-P2rx7tm1Gab/J,
Jackson Laboratories, Bar Harbor, ME, USA), gld/gld
mice (C3H/HeJ-Jms, FasL-deficient, SLC, Japan), and
wild-type (WT) littermates of both backgrounds were
used for the experiments. All of the animal procedures
conformed to appropriate guidelines for the care and
use of laboratory animals and were approved by the
Committees for Animal Experiments of Zhejiang Uni-
versity in China and Tohoku University in Japan.
Cerebral microemboli model
The microsphere embolism model was prepared as pre-
viously described [5]. Briefly, male Wistar rats weighing
220 g to 270 g were subjected to general anesthesia, after
which 1,000 non-radioactive microspheres (48.4 ± 0.7 μm
in diameter) were injected into the left carotid artery.
The rats were decapitated 2, 6, 12, 24, 72, or 168 h after
microsphere injection, and the ipsilateral cerebral hemi-
sphere was dissected for further analysis. For P2X7
−/−
mice, gld/gld mice, and their respective WT littermates,
5,000 non-radioactive microspheres (15 μm in diameter)
were injected into the left carotid artery. Neurological
scores were assessed 168 h after microsphere embolism
as previously described [5].
MicroPET scans
2-[18F]-fluoro-2-deoxy-D-glucose (18F-FDG) injections
and microPET scans were processed as previously
reported [26]. The data of 18F-FDG microPET imaging
were acquired from rats 168 h after microsphere embol-
ism by using a microPET R4 scanner (Concorde Micro-
systems, Knoxville, TN, USA).
Drug treatment
Drug administration began after a 1-day recovery period
following microsphere embolism in rats. Minocycline
hydrochloride (Sigma-Aldrich) (45 mg/kg, dissolved in
distilled water) was intraperitoneally administered daily
for 6 consecutive days. The ipsilateral hemispheres were
then dissected for western blot analysis.
Oxygen-glucose deprivation and neuron-conditioned
medium
Cortical neurons were prepared from E18 C57BL/6
mouse embryo cortices as previously described [27]. The
mice were decapitated to minimize pain and distress.
Dissection and dissociation were carried out in 1×
Hank’s balanced salt solution (HBSS) and 0.25% trypsin
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(Gibco) for 10 min before being terminated with 1×
HBSS and 10 mg/mL trypsin inhibitor. Neurons were
also dissociated by trituration in HBSS containing
DNase I with a flame-narrowed pasteur pipette to fully
dissociate the cells. Neurons were seeded at an approxi-
mate density of 2 × 107 on 6-cm dishes (430166, Corn-
ing) and maintained in 5 mL of neurobasal medium
containing B27 supplement (2%, Invitrogen), penicillin-
streptomycin (100 U/mL penicillin, 100 μg/mL strepto-
mycin, Gibco) and 0.25% GlutaMAXTM-1 (Gibco).
Neurons were grown in vitro for 7 days.
To create an in vitro ischemia-like injury model, the pri-
mary cortical neurons were subjected to oxygen-glucose
deprivation (OGD). The procedure for OGD challenge was
performed as previously reported [6]. The medium was
removed from the cultures, and the cells were rinsed twice
with glucose-free HBSS prior to being subjected to OGD at
defined time points. The OGD-treated cell-free conditioned
medium (OCM) was collected to perform related analyses.
BV-2 murine microglial cells culture and migration assay
BV-2 murine microglial cells, which exhibit similar mor-
phological and functional properties comparable to pri-
mary microglial cells [28,29], were grown in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal
bovine serum at a density that did not exceed 5 × 105
cells/mL. To mimic ischemia-like injury, the BV-2
immortalized mouse microglial cell line was subjected to
OCM. Migration was assessed with a transwell migration
chamber as described in a previous report [30]. Briefly,
BV-2 murine microglial cells were placed in a transwell
migration chamber and cultured in DMEM medium
supplemented with 10% fetal bovine serum (FBS) at a
density of 2 × 105 cells/mL. The cells were allowed to
migrate through a polycarbonate mesh (8.0 μm pore
size, polycarbonate membrane, Corning Costar Corp.,
Cambridge, MA, USA) at 37°C. For the experiments that
used neutralizing antibody, the cells were preincubated
with anti-mouse FasL neutralizing antibody (2 μg/mL,
8 μg/mL, or 16 μg/mL; Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA, Catalog no: sc-19988) or control
preimmune serum for 30 min before ATP or recombin-
ant FasL treatment. Recombinant FasL (100 ng/mL,
Sigma-Aldrich, Catalog no: F0552) was placed in the
lower chamber to induce migration. The chamber was
kept in 5% CO2 at 37°C for 24 h. Microglia that migrated
to the lower surface were fixed with 4% paraformalde-
hyde and stained with the blue-fluorescent DAPI. The
rate of microglial migration was calculated by counting
the cells of each well using a 10× bright-field objective.
The number of cells in each well was normalized to the
average number of cells in the control condition (100%).
The experiments were repeated at least three times.
Lentiviral infection
To construct the P2X7 short hairpin RNA (shRNA) expres-
sion plasmid, two complementary P2X7 DNA oligonucleo-
tides (see below) were synthesized, annealed, and inserted
into the pMagic 4.1 plasmid. Reduction of P2X7 expression
was achieved through lentiviral infection of BV-2 microglia
with the P2X7 cDNA coding sequence 5’-GCAAGTT
GTCAAAGGCCAA-3’, and the resulting culture super-
natant was used for the lentiviral infection. As a control,
microglia were infected in a similar manner with the
shRNA sequence 5’-TTCTCCGAACGTGTCACGT-3’.
The cells were collected for further experiments at 72 h
postinfection.
RNA interference of FasL expression
FasL siRNAs (Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA) were introduced into BV-2 murine microglial
cells with transfection medium according to the manufac-
turer’s instructions. The control set of BV-2 cells was trans-
fected with non-targeted siRNAs. The cells were collected
for experiments 24 h after transfection. Knockdown was
confirmed with western blotting using whole cell lysates.
ELISAs for extracellular Fas ligand
BV-2 murine microglial cells were either infected with
lentivirus directing the expression of non-targeting con-
trol or P2X7-specific shRNAs or transfected with siRNAs
against FasL. Supernatants from the OGD-treated cor-
tical neurons were applied to BV-2 cultures for the
measurement of the FasL level. Target cells were then
cultured with OCM for 6 h, and Fas ligand assays were
performed with a mouse Fas ligand/TNFSF6 immuno-
assay kit (R&D Systems, Minneapolis, MN, USA) follow-
ing the manufacturer’s protocol.
Primary microglial cell culture and chemotaxis assays
Primary mixed glial cultures were prepared according to a
previously described method with slight adjustments [31].
Briefly, mixed glial cultures were prepared from the cere-
bral cortices of 1-day-old mice using 0.25% trypsin, and the
cells were cultured in minimal essential medium (MEM)
containing 10% FBS(Gibco) at 37°C in a 5% CO2 humidi-
fied incubator. After 10 to 14 days, the cultures were
shaken by hand for 15 min, the floating cells were collected
and centrifuged for 5 min at 1000×g, and microglial cells
were seeded on glass-bottom dishes (Matsunami, Osaka,
Japan) at a density of 2 × 104 cells per dish.
For the chemotaxis assays, the cells were exposed to a
chemoattractant gradient that was generated by slowly
releasing ATP from a micropipette tip that was placed at
the center of the imaging field. Cell migration toward
the pipette tip was monitored over a 30-min period by
phase-contrast time-lapse microscopy. Acquisition was
performed using an Olympus microscope with a × 20 air
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objective (LCACH, 0.4 NA), and the images were pro-
cessed and analyzed using Fluoview software (FV10-
ASW 5.0, Japan) [32].
Western blotting
Proteins were extracted, and the soluble cytosolic frac-
tion was isolated according to our previous study [5].
Samples containing equivalent amounts of protein were
loaded onto 10% to 15% acrylamide denaturing gels (so-
dium dodecyl sulfate polyacrylamide gel electrophoresis;
SDS-PAGE). Membranes were probed overnight at 4°C
with antibodies against Fas (sc-736), FasL (sc-6237),
P2X7 (sc-25698), High mobility group box 1 (HMGB1,
sc-26351), caspase-8 (sc-7890) (Santa Cruz Biotechnol-
ogy Inc., Santa Cruz, CA, USA); CD3 (Abcam Cam-
bridge, UK, Catalog no: ab5690); FADD (Epitomics, Inc.,
Burlingame, CA, USA, Catalog no: 2988–1); and β-actin
(Sigma Chemical, St Louis, MO, USA, Catalog no:
A2228). Immunoreactive proteins were visualized using
an enhanced chemiluminescence detection system
(Amersham Life Science, Buckinghamshire, UK).
Fluoro-jade C staining
Fluoro-Jade C is a fluorescein derivative that has been
shown to specifically stain degenerating neurons. In ac-
cordance with previous studies [33], free-floating sections
were immersed in a 0.06% potassium permanganate solu-
tion for 10 min and then rinsed in distilled water for
1 min. The slides were then transferred to Fluoro-Jade C
(Millipore) staining solution (0.001%) for 10 min. After
staining, the sections were rinsed three times for 1 min
each in distilled water.
Immunohistochemical labeling, image acquisition, and
analysis
Animals were anesthetized and transcardially perfusion-
fixed with 4% paraformaldehyde in phosphate-buffered
saline (PBS). Whole brains were immediately removed
and postfixed overnight at 4°C in the same fixative. To
identify distribution of microglial nodule in the brain,
paraffin sections (4 μm) were stained with hematoxyli-
neosin (H&E). For immunolabeling, coronal brain sec-
tions at the coordinates of anterior or posterior to
bregma (35 μm in thickness) were prepared using a
microslicer system (Vibratome, St Louis, MO, USA).
Then, brain sections were incubated at room
temperature with 0.01% Triton-X-100 in PBS for 30 min,
followed by incubation in 3% bovine serum albumin
(BSA) in PBS for 1 h. For immunolabeling, sections were
incubated with antibodies to FasL (sc-6237) and P2X7
(sc-25698) (Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA); GFAP (Sigma Chemical, St Louis, MO, USA,
Catalog no: G3893); ED1 (MAB1435) and NeuN
(MAB377) (Chemicon, Temecula, CA, USA); and Iba1
(Abcam Cambridge, UK, Catalog no: ab5076) overnight
at 4°C, followed by exposure to fluorescent secondary
antibodies according to a standard protocol from Perki-
nElmer Life Sciences, Inc. (Boston, MA, USA). Immuno-
fluorescent images were taken with a confocal laser
scanning microscope, and fluorescent density was ana-
lyzed using Image J software (NIH, Bethesda, MD, USA).
Statistical analysis
The data are represented as the mean ± SEM. Statistical
significance was determined using one-way analysis of
variance (ANOVA) followed by Dunnett’s test for multi-
group comparisons. A non-parametric Mann–Whitney U-
test was used for analysis of the neurologic deficit data. P
<0.05 indicated statistically significant differences.
Results
Microsphere embolism-induced damage to microvessels
caused a focal response in neighboring microglial cells
Microsphere embolism is a useful model to mimic the
pathological process of human stroke or multi-infarct de-
mentia; injected microspheres with appropriate size and
number can specifically elicit microcapillary embolization
rather than the larger artery injury [4-6]. Figure 1A shows
that microsphere embolism induced decreasing of meta-
bolic activity of glucose at 168 h after microspheres injec-
tion by using the microPET scanner. We also attempted to
address the relationship between microsphere embolism
and microglial activation in the ipsilateral hemisphere.
After 168 h, we observed ED1-positive cells with ameboid
morphology surrounding occluded microvessels in the rats
with microsphere-induced embolism (Figure 1B and 1C).
Temporal changes in FasL levels in rats following
microsphere embolism
FasL-Fas system is key initiators of the inflammatory re-
sponse to injury [11]. To determine the roles of the Fas
and FasL in microsphere-induced embolism, we initially
used immunoblotting to investigate the temporal profile
of FasL/Fas protein expression levels following micro-
sphere embolism. A 40-kDa FasL immunoreactive pro-
tein band was detected by SDS-PAGE (Figure 2A).
Representative blots are presented in Figure 2 and show
a significant increase in FasL protein after 12 h in ME
rats compared with sham rats (222.1 ± 15.6% vs. sham, P
<0.05; Figure 2A and 2B). Further increases in FasL
were evident after 168 h in the rats with microsphere
embolism compared with the sham rats (348.1 ± 35.4%
vs. sham, P <0.01). However, no significant differences
in Fas expression were found (48 kDa) throughout the
experiments (Figure 2A and 2B).
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FasL production is associated with microglial activation
following microsphere embolism
To identify which cell types could potentially mediate the
observed FasL signaling, we used double immunostaining
for cell-specific markers to examine the cellular localization
of FasL 168 h after the injection of microspheres. As shown
in Figure 2C, the distribution patterns of FasL deposits and
NeuN-positive staining were significantly different. In sham
rats, the injection of 20% dextran did not induce an eleva-
tion in FasL expression (Figure 2C). A significant number
of FasL-expressing cells, which were diffusely labeled with a
round morphology, were found to be restricted to the oc-
cluding region 168 h after microsphere embolism
(Figure 2C, d). In addition, astrocyte activation is known to
be a significant component of postischemic pathophysi-
ology [4]. A comparison of GFAP and FasL immunoreactiv-
ities demonstrated a near-complete dissociation of the
staining patterns for these proteins in the ipsilateral hemi-
sphere in ME rats (Figure 2D, d, e, f). Nearly all FasL-
positive cells co-localized with ED1 (Figure 2E, f), whereas
sham rats did not show significant positive staining for FasL
or ED1 (Figure 2E, c).
The co-localization of fluorescent signals was analyzed
using Image J software. NeuN and GFAP weakly co-
localized with FasL-positive cells (FasL/NeuN, 16.4 ± 9.9%;
FasL/GFAP, 5.5± 3.6%), whereas FasL strongly co-
localized with ED1 (the mean overlapping fraction,
76.2± 12.3%; Figure 2F). Both Pearson’s r index and an
Figure 1 Microsphere embolism-induced damage to microvessels caused a focal response in neighboring microglial cells. (A) Changes
in metabolic activity of glucose 168 h after microsphere embolism (ME) imaged on the microPET scanner. Images were taken from the same scan
and reconstructed using the maximum a posteriori probability algorithm. Arrows indicates the ipsilateral hemisphere of rat brain. (B) Fluorescent
staining with anti ED1 antibodies indicates predominant microglia activation beside the region blocked by microspheres (arrow). A number of
activated microglia appeared to associate with a more distal region of the vessel as shown in the longitudinal section (a) and cross section (b).
(C) Activated microglia were also found surrounding microsphere region (outlined in red), is shown in a series of XZ reconstructions. DAPI
counterstaining indicates cell nuclei (blue). Scale bar = 50 μm. ME, microsphere embolism.
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intensity correlation coefficient (ICQ) analysis indicated
similar results (Figure 2F). The present data indicate that
robust FasL expression is predominantly associated with
activated microglia after microsphere embolism in rats.
Immunohistochemical localization of ED1- and Iba1-
positive cells in the microembolic brain
We further assessed longitudinal changes in ED1 expres-
sion after microsphere embolism. ED1 protein levels signifi-
cantly increased in the brains of ischemic rats 6 h and 12 h
(acute phase) after microsphere embolism compared with
sham-operated rats. A secondary increase in ED1 was
observed after 72 h, and the level remained elevated
through 168 h (subacute phase) after microsphere embol-
ism (Figure 3A, B). Consistent with previous reports, the
early transient increase in ED1 might be associated with an
adaptive immune response of microglial function to com-
pensate for ischemic brain injury [34]. Indeed, we observed
rapid activation of microglia in response to microembolic
injury (apparent as early as 2 h after the event) that
Figure 2 Changes in FasL expression after microsphere embolism induction in the brain. (A) Representative immunoblots showing Fas
and FasL expression at the indicated times following microsphere embolism in rats. Immunoblotting with an anti-β-actin antibody showed equal
total protein loading in each lane. S, sham. (B) Quantitative analysis of Fas and FasL levels was performed by densitometric analysis of the
immunoblots. The data are expressed as percentages of values obtained from sham animals (mean ± SEM, n= 6 rats). *P <0.05; **P <0.01 vs.
sham. (C) Fluorescent staining for FasL (green) and NeuN (red) was performed in ipsilateral brain regions 168 h after embolic injury in rats. (D)
FasL (green, a, d) and GFAP (red, b, e) double staining was performed 168 h after embolic injury in rats. (E) Immunohistochemical localization of
FasL (green) and ED1 (red) was examined 168 h after ME ischemia. Scale bar = 40 μm. (F) Quantification of colocalized FasL-NeuN, FasL-GFAP, and
FasL-ED1 fluorescent signals in rats following ME injury. The mean overlapping fraction, the mean Pearson’s r and the mean ICQ are presented for
each condition (the mean ± SEM, n=6 rats). ME, microsphere embolism.
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occurred with subsequent morphological changes similar to
those observed in the late phase of microsphere embolism
(data not shown). In the present study, the sources of lym-
phocytes and monocytes were examined using assays for
CD3 and HMGB1, respectively. We did not find any signifi-
cant differences in these markers after cerebral microemboli
at any time point examined (Figure 3A, B). Concurrently,
H&E staining indicated the presence of microglial nodules
throughout the brain ipsilateral hemisphere to the micro-
sphere embolism, whereas no infiltration of leukocytes,
monocytes, or macrophages was observed (Figure 3C).
Taken together, these data suggest that activated microglia
might be the predominant source of FasL after microsphere
embolism.
We also confirmed the specific activation of microglia
during cerebral microemboli by immunostaining for Iba1,
which is ubiquitously expressed in all microglial popula-
tions [35]. Double-labeling studies revealed that the number
of Iba1/ED1-positive cells and the corresponding fluores-
cence intensity increased significantly in ME animals, in-
cluding both ramified (12 h after microsphere embolism)
(Figure 3D, d-f) and typical ameboid microglia (168 h after
microsphere embolism (Figure 3D, g-i)). In addition, Iba1
and ED1 were present in the same cell populations in the
Figure 3 Microsphere embolism induces microglia activation in brain of experimental animals. (A) Temporal changes in ED1, HMGB1, and
CD3 expression in ME rats. (B) Quantification of the normalized protein levels shown in (A). The data are expressed as percentages of values
obtained from sham animals (mean ± SEM, n= 6 rats). **P <0.01; ***P <0.001 vs. sham. (C) H&E staining indicated that the presence of microglial
nodules was noted ipsilateral to microsphere embolism. No infiltration of leukocytes, monocytes or macrophages was observed. Scale
bar = 200 μm. (D) Immunohistochemical localization of ED1 (red)- and Iba1 (green)-positive cells in the microembolic brain. Iba1 labeling was
used to identify the microglial population. Double-labeling studies revealed that Iba1 and ED1 staining were present in the same cell populations
in areas of ME injury. Scale bar is 50 μm (a-i) and 20 μm (j, k, l). (E) Co-localization between the Ki-67 antigen and ED1-immunoreactive microglial
cells in the ipsilateral region of brain. Scale bar = 50 μm. ME, microsphere embolism.
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ischemic region (Figure 3D, f and i). The observed irregular-
ities in microglial cell shape support the possibility that the
degree of morphological changes in Iba1/ED1-immunor-
eactive microglial cells is proportional to the duration of is-
chemic injury. The Ki-67 antigen is preferentially activated
during all of the active phases of the cell cycle, but it is ab-
sent in resting cells. We found co-localization between the
Ki-67 antigen and ED1-immunoreactive microglial cells in
the ipsilateral brain region (Figure 3E).
FasL elevation is associated with the migration of BV-2
microglia cells
To investigate whether sustained FasL elevation is asso-
ciated with the migratory capacity of microglia, we per-
formed an in vitro transwell migration assay by using BV-
2 cell line. In the present study, we found that FasL was
rapidly elevated in response to OGD-treated cell-free con-
ditioned medium (OCM) in the cultured BV-2 (Figure 4A)
and peaked at 6 h after treatment (this peak was not
observed in the control condition). Moreover, recombin-
ant FasL (100 ng/mL) was added to microglial cultures,
and the migration of cells were observed after a 24 h treat-
ment with or without FasL antibody. The bar graph in
Figure 4C summarizes the results from Figure 4B. These
results demonstrate that recombinant FasL significantly
promotes the migration of immortalized BV-2 microglia
cells by 4.7-fold compared with the control cells
(Figure 4A, B). Functionally, neutralizing FasL with block-
ing antibody was highly effective in inhibiting microglial
mobility and chemotactic responses (FasL antibody 8 μg/
mL, 70.69± 12.06% vs. Control; Figure 4C).
P2X7 signal contributes to OGD-triggered immune
responses by maintaining the overproduction of FasL in
microglia cells
In the brain parenchyma, injured cells release purines that
initiate P2X7 purinergic signals, which act as early proin-
flammatory signals and lead to the production of cytokines
and chemokines [36-38]. Therefore, we examined whether
P2X7 expression could also regulate FasL production in cul-
tured microglia, and we investigated the potential mechan-
isms associated with this process. Blockade of P2X7
signaling by P2X7-specific shRNA transfection significantly
suppressed OCM-induced FasL production in the culture
supernatants, whereas P2X7 shRNA alone did not affect
FasL levels (Figure 5A), which indicated a causative role for
P2X7 in initiating microglia-mediated FasL generation.
Western blotting of BV-2 microglial cell lysates showed that
microglia expressed FasL 6 h after the OCM treatment
(Figure 5B, C). The suppression of P2X7 activation with
P2X7 shRNA significantly prevented OCM-induced FasL
expression but did not affect Fas expression (Figure 5B, C).
These findings further support the idea that enhanced
P2X7 expression may act as an important upstream
regulator of FasL formation in OCM-treated microglial
cells. These results highlight the ability of neuron-
conditioned culture medium from OGD-stimulated cortical
neurons to maintain a controlled inflammatory state
through the activation of a P2X7-FasL signal that favors the
microenvironment of activated microglia.
To ascertain whether OCM-induced increase in FasL
protein required new mRNA and/or protein synthesis in
Figure 4 FasL elevation is associated with the migration of
microglia in BV-2 microglia cells. (A) OCM treatment promotes
FasL generation in BV-2 cells in a time-dependent manner. (B)
Representative images of FasL-induced migration of microglia with or
without the presence of FasL antibody. Scale bar = 100 μm. (C)
Quantitative data of microglial migration following recombinant FasL
treatment with or without FasL antibody pretreatment. **P <0.01 vs.
Control; #P <0.05 versus recombinant FasL treatment alone.
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microglial cells, we examined FasL levels in BV-2 cells
treated with either the protein synthesis inhibitor aniso-
mycin or the RNA polymerase inhibitor actinomycin D.
We pretreated BV-2 cells with anisomycin or actinomycin
D prior to treating them with OCM (Figure 5D). We
found that the synthesis of FasL in microglia was sensitive
to anisomycin treatment (Figure 5D). Concomitantly, acti-
nomycin D pretreatment also decreased OCM-induced
FasL elevation in BV-2 cells, indicating that OCM-induced
FasL protein synthesis might dependent on new mRNA
expression (Figure 5D). Thus, the present data suggest
that OCM activates the local translation of FasL protein in
a transcription-dependent manner. These results rule out
the possibility that P2X7 knockdown might affect the gen-
eral microglia protein translation machinery and suggest
that P2X7 signaling is selectively involved in ischemia-
induced microglial activation.
FasL is required for microglial migration
Moreover, a transwell assay was used to examine whether
P2X7 plays a role in exogenous recombinant FasL-
mediated microglial migration. We found that FasL siRNA
transfection effectively reduced the number of BV-2
microglia that migrated toward the lower chamber relative
to the control cells that only contained recombinant FasL
(Figure 6A). However, P2X7 shRNA transfection did not
significantly affect the exogenous recombinant FasL-
mediated microglial migration (Figure 6A). These data fur-
ther enforced the idea that P2X7 act as an upstream regu-
lator of FasL production in activated microglial cells.
In light of the proposed roles for purinergic receptors in
regulating microglial motility, we further investigated
whether P2X7
−/− mice showed deficits in cellular responses
to exogenous ATP. Upon application of Adenosine 5’-[γ-
thio] triphosphate tetralithium salt (ATPγS, 1 mM), the vast
Figure 5 P2X7 signal contributes to the migration of microglia in BV-2 microglia cells. (A) P2X7-specific shRNA transfection significantly
reduced the increase in FasL generation induced by the OCM from OGD-stimulated cortical neurons. **P <0.01 vs. Control; #P <0.05, ##P <0.01 vs.
OCM treatment alone. (B) OCM-induced FasL protein expression was abolished by lentiviral infection of P2X7-shRNA in the BV-2 cell line.
Quantified data are shown in (C). **P <0.01 vs. Control; #P <0.05 vs. OCM treatment alone. (D) Representative immunoblots (upper) and
quantitative analyses (lower) for FasL from BV-2 cultures following actinomycin D or anisomycin treatment. *P <0.05 vs. Control; #P <0.05 vs. OCM
treatment alone. OCM, OGD-treated cell-free conditioned medium.
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majority of microglia from WT mice showed robust migra-
tion on time-lapse recordings (Figure 6B). In contrast,
microglia cells from the P2X7
−/− mice did not show signifi-
cant chemotactic response to ATP. Notably, preincubation
with FasL antibody (8 μg/mL) significantly diminished the
ATP-evoked chemotactic response of WT microglia
in vitro (Figure 6B; see Additional file 1: Movie 1, Add-
itional file 2: Movie 2 and Additional file 3: Movie 3).
Therefore, these results further suggest the critical func-
tional roles for P2X7-FasL signaling in mediating microglial
chemotactic inflammatory responses.
P2X7 is up-regulated in microglia after microsphere
embolism
The experiments described above suggest that P2X7 is
associated with the microglia-derived FasL overproduc-
tion. Therefore, we next investigated biochemical and
morphological changes in P2X7 purinoceptors in cerebral
microvascular occlusion models. Notably, we observed a
dramatic and continuous increase in P2X7 immunoreac-
tivity 6 h after microsphere embolism, which was consist-
ent with the rapid activation of microglia (Figure 7A).
Dual labeling of P2X7 and ED1 was used to ascertain
whether the microsphere embolism-induced activation of
microglia occurred in conjunction with P2X7 receptor-
dependent signaling. Consistent with previous studies
[39], we found that 168 h after microsphere embolism, the
majority of P2X7 immunoreactivity localized to activated
microglia (Figure 7B, d-f).
Microglia-induced neuronal injury in conjunction with
P2X7 purinoceptor-FasL pathway activation
The increase in P2X7 expression in microglia during
microsphere embolism suggested a potential functional
role for P2X7 in this process. To test this hypothesis, we
subjected P2X7
−/− mice to 168 h of microsphere embolism.
Figure 6 FasL is required for microglial migration. (A) A transwell
assay was used to examine whether FasL silence or lentiviral infection
of P2X7-shRNA could attenuate recombinant FasL-mediated microglial
migration. **P <0.01 vs. Control; ##P <0.01 vs. recombinant FasL
treatment alone. (B) FasL antibody neutralization or the loss of P2X7
receptors abrogates the response of microglia to ATP in primary
microglial cell culture. Microglia from wild-type or P2X7
−/− mice
visualized using time-lapse microscopy. Exuberant process extension
toward a source point of ATPγS (1 mM from injection needle, red) was
observed in the microglia of wild-type but not P2X7
−/− mice or
preincubation with FasL antibody. Scale bar = 20 μm.
Figure 7 P2X7 participates in microsphere embolism-induced
microglial activation. (A) Temporal changes in P2X7 receptor
expression levels after microsphere embolism induction in rat brain.
The results are represented as the mean ± SEM, n= 6 rats. *P <0.05
and **P <0.01 vs. sham rats. (B) Immunohistochemical localization of
P2X7- and ED1-positive cells in the microembolic brain. Scale
bar = 20 μm. ME, microsphere embolism.
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This time point was chosen because markers of cellular in-
flammation are robust in embolic injured brain at 168 h.
Notably, neurological deficits were reduced in P2X7
−/− mice
compared with strain-matched WT mice (Figure 8A). Con-
sistent with these data, brains from the P2X7
−/− mice
showed less induction of FasL, FADD, and caspase-8 after
168 h of microsphere embolism compared with WT con-
trols (Figure 8B, C). In addition, less FasL-positive staining
was observed in P2X7
−/− mice compared with WT mice
(Figure 8D). The present study also implicated that ele-
vated FasL levels are correlated with clinical severity of
microsphere embolism.
To conclusively demonstrate the significance of FasL in
ischemic injury in vivo, we also tested the neural sensitivity
to cerebral microemboli insult in gld/gld mice. An increase
in the number of Fluoro-Jade C-positive cells was observed
in WT mice following microsphere embolism, whereas few
Fluoro-Jade C-positive cells were present in FasL-deficient
mice (Figure 8E). In addition, microsphere embolism sig-
nificantly induced microglia activation and increased the
number of FasL-positive cells in the brain ipsilateral hemi-
sphere in WT mice, whereas both ED1- and FasL-positive
staining were sparse in gld/gld mice 168 h after micro-
sphere injection (Figure 8F).
Figure 8 Microglia-induced neuronal injury in conjunction with P2X7/FasL pathway activation. (A) Neurological scores were determined
168 h after microsphere embolism in P2X7
−/− mice. The data are expressed as the mean± SEM (n= 6 mice). *P <0.05 vs. WT mice. (B)
Immunoblots demonstrating FasL/Fas cell death signaling measured 168 h after microsphere embolism in P2X7
−/− and WT mice. Quantified data
are shown in (C). Data are expressed as means ± SEM (n= 6 mice). *P <0.05; **P <0.01 vs. Sham (WT); #P <0.05 vs. ME (WT) group. S-WT, Sham
(wild type). (D) Decreased FasL immunostaining was observed in P2X7
−/− mice 168 h after ME. DAPI counterstaining indicates cell nuclei (blue).
Scale bar = 100 μm. (E) Fluoro-Jade C staining demonstrating the degree of neurodegeneration in WT and gld/gld mice 168 h after ME. Scale
bar = 50 μm. ME, microsphere embolism. (F). Immunohistochemical staining of FasL and ED1 in the ischemic brains of WT and gld/gld mice 168 h
after ME. Scale bar = 50 μm.
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ME-induced FasL activation and the apoptosis cascade
are inhibited by minocycline treatment
Minocycline has emerged as a potent inhibitor of micro-
glial activation, which is a member of the tetracycline
antibiotic family [40,41]. It is interesting to consider
whether peripheral administration of minocycline also
affect microglia-derived increasing of FasL. As shown in
Figure 9 (B, C), the protein level of FasL and FADD sig-
nificantly increased 168 h after microsphere embolism,
whereas prolonged minocycline treatment significantly
inhibited elevation of FasL, which paralleled with the
decreased FADD expression. These results further en-
force that activation of microglia is linked with down-
stream FasL production in microglia. Concomitantly, we
also found that prolonged minocycline treatment lead to
improvement in neurological function (Figure 9A).
Discussion
The present study addressed the pathophysiological rele-
vance of cerebral microembolic injury-induced micro-
glial activation, FasL intracellular signaling, and the
neuronal death cascade. The primary findings of this
study are three-fold. First, during the pathological
process of cerebral microembolic injury, FasL signaling
associated with ischemia-initiated microglial activation.
As a key microenvironmental signal, overproduction of
FasL further stimulated an extensive microglial response
in an autocrine manner. Second, the effective inhibition
of microglial activation was observed with P2X7 shRNA
infection in cultured microglia or P2X7
−/− mice in vivo,
and the inhibition of microglial activation was paralleled
by inhibition of ischemia-induced FasL overgeneration.
Third, permanent cerebral microemboli induced mor-
phological and biochemical reactions in microglia that
were consistent with neuronal apoptotic cascades. Based
on the present findings, we hypothesize that modulation
of microglial neurotoxicity may prove to be a potential
therapeutic target in neurovascular diseases.
Several prior studies have revealed that microglia play
a crucial role in mediating inflammatory responses fol-
lowing the initial insult [21,42-44]. Consistently, the
present study demonstrates the rapid activation of
microglia in response to microembolic injury, which is
apparent as early as 2 h after the event. The robust FasL
expression is predominantly associated with activated
microglia in subacute phase of microsphere embolism.
Several recent studies reported that purinergic receptors
are involved in brain ischemia [39,45]. However, the re-
lationship between microglial activation, FasL generation
and neuronal death is not well understood and may in-
volve multiple intracellular components [46-48]. In the
present study, a rapid increase in P2X7 purinoceptor ex-
pression occurred in parallel with the early microglial ac-
tivation in response to permanent microemboli injury,
and P2X7 were predominantly expressed in ED1-
expressing microglial cells. The P2X7 purinoceptor-
mediated Ca2+ influx and activation of phospholipase C
and the A2 cytoplasmic signaling pathways may be
involved in proinflammatory cytokine release [36,49].
Here, the BV-2 cells with RNA interference and P2X7
−/−
mice were used to further address the linkage between
P2X7 and FasL overproduction. Our data revealed that
FasL production was increased in the OCM-treated BV-
2 cells, whereas P2X7 interference partially but signifi-
cantly prevented this OCM-induced FasL overproduc-
tion. Similar results were also observed in P2X7
−/− mice
with microsphere embolism in vivo. Monif et al. [50]
reported that the overexpression of P2X7 purinoceptors
was sufficient to drive microglial activation and morpho-
logical transformation. Therefore, we suggested that
P2X7 purinoceptor may be an important upstream com-
ponent of FasL generation, the activation of P2X7 in
microglia contributes to a gradual accumulation of FasL
along with the subsequent activation of downstream
cascades.
The autocrine action of FasL-Fas system has been
shown in vascular smooth muscle cells [14], lymphocytes
[16], and leukemia K562 cells [51]. In the present study,
the BV-2 cells and primary microglia from mice genetic-
ally deficient in P2X7 were used to further establish a
Figure 9 Microsphere embolism-induced FasL activation and
the apoptosis cascade were inhibited by minocycline treatment
in ME rats. (A) Neurological scores were determined 168 h after ME
with or without minocycline treatment. Data are expressed as
means ± SEM (n= 6 rats). *P <0.05 vs. vehicle-treated rats. (B)
Immunoblots demonstrating FasL/Fas cell death signaling measured
168 h after ME with or without post-treatment with minocycline.
Quantified data are shown in (C). Data are expressed as means ±
SEM (n= 6 rats). *P <0.05; **P <0.01 vs. Sham; #P <0.05 vs. ME
group. ME, microsphere embolism.
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linkage between microglia activation and FasL overpro-
duction. Of particular relevance was an examination of
microglial cultures with recombinant FasL treatment,
which revealed that recombinant FasL significantly trig-
gered microglia migration whereas was blocked by FasL
antibody. In functional terms, we found that the levels of
FasL generation agreed with the kinetics of migration of
BV-2 cells. The microglial-mediated inflammatory auto-
crine responses involving cytokines are one important
consideration in the pathology of neurovascular damage
[52-54]. We suggested that the overproduction of FasL
itself is sufficient functions as a key component of
immunoreactive response loop by recruiting microglia to
the lesion sites. Moreover, preincubation with FasL anti-
body significantly diminished the ATP-evoked chemo-
tactic response of primary microglia in vitro. Therefore,
we suggested that OGD-induced, microglia-derived FasL
might be a key microenvironmental signal, which stimu-
lated an extensive microglial response in ischemic
context.
Tight regulation of microglial activation might be
exploited to avoid unexpected and excessive cell death in
the compromised brain [13]. We found that the deletion of
P2X7 purinoceptors in vivo using P2X7
−/− mice significantly
reduced the expression of FasL and concomitantly neur-
onal cell death in the embolic hemisphere of brain, which
implicated that a constitutive elevation of FasL might act
in concert with P2X7 to induce neurotoxicity. Mutations in
Fas ligand are responsible for the single gene autoimmune
gld phenotypes in mice [55]. Here, our data further indicate
that gld/gld mice deficient in FasL were highly resistant to
ischemia-induced neuronal damage. In addition, we found
that minocycline treatment inhibited FasL signaling and
subsequently reduced neuronal cell death in animals after
microsphere embolism, which further suggested that
microglia-derived FasL might contributes to a vicious cycle
of neuronal cell death. Together, in vivo data also support
the idea that P2X7 is involved in regulating the pathological
immune response of microglia to microsphere-induced
embolism via maintaining the activation of FasL.
The astrocyte-microglia collaboration forms a first-line
innate immune mechanism in the parenchyma to detect
mediators released from injured cells [56-58]. Whether
FasL generation by activated microglia contributed to the
activation of astrocytes in the present study, however, is a
topic for further investigation. Additionally, when activated
microglia change into a chronic profile following an injury,
the cells either maintain their acute phenotype or divert
into another activation state, may be chronically beneficial
for neuronal survival and differentiation [10,59]. Therefore,
to elucidate the role of P2X7/FasL signaling during chronic
phase of ischemia should enable further progress to be
made in the therapeutic translation of experimental obser-
vations to the bedside.
Conclusion
Based on our observations, the present study used the
cerebral microemboli model and an in vitro culture system
to provide further evidence of a role for microglial activa-
tion and P2X7/FasL-Fas signaling following ischemic in-
sult. We demonstrate a new role for FasL in cerebral
microvascular occlusion-mediated inflammatory responses
and a previously unknown P2X7-based mechanism. In
particular, these results also describe a mechanism that
immunoreactive response loop of microglia-derived FasL
further exaggerates P2X7-mediated microglial activation
and triggers a vicious cycle of neuronal cell death in the is-
chemic context (Figure 10). The present results highlight
the potential for a novel therapeutic neuroprotective ap-
proach using pharmacological blockade of sustained
microglial activation and the death-inducing ligand in the
acute and subacute phase of ischemia.
Additional files
Additional file 1: Movie 1 (For Figure 6B). Migration of microglia
from wild-type mice was recorded by time-lapse recording after
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microglia from P2X7 knock out mice was recorded by time-lapse
recording after exposure to a gradient of ATPγS (1 mM) for 30 min.
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antibody (8 μg/mL) diminished the ATPγS (1 mM)-evoked migration of
microglia from wild-type mice.
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